Grail Cancer Test Fails, FDA AI Hire & SSRI Review – Biotech News

Recent developments in biotech and pharmaceutical regulation reveal both setbacks and shifts in focus. A key trial for Grail’s Galleri blood test has missed its primary endpoint, raising questions about the promise of early cancer detection. Simultaneously, the Food and Drug Administration (FDA) is undergoing internal changes with the appointment of an AI industry veteran to lead its digital health initiatives, and a new chief is prioritizing review of existing treatments.

Setback for Multi-Cancer Blood Test

Grail’s Galleri blood test, designed to detect multiple types of cancer, recently failed to meet the primary endpoint of a crucial trial conducted with the National Health Service (NHS). This outcome has prompted a re-evaluation of whether earlier cancer detection, through tests like Galleri, translates into improved patient outcomes or simply accelerates the timing of diagnoses. The failure of the trial has already had a significant financial impact, with Grail’s stock plummeting more than 45% after hours on Thursday.

Did You Know? Grail partnered with digital health companies Function Health and Everlywell to offer the Galleri test.

Changes at the FDA

The FDA is also experiencing changes. The agency has appointed a leader with experience in artificial intelligence to steer its digital health strategy. Tracy Beth Høeg, the new chief of the centre for Drug Evaluation and Research (CDER), has indicated her intention to revisit the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and to closely scrutinize respiratory syncytial virus (RSV) monoclonals.

Expert Insight: The Galleri trial failure underscores the complexities of evaluating new cancer detection technologies. While early detection is often seen as beneficial, demonstrating a clear link between earlier diagnosis and improved survival rates remains a significant challenge.

The implications of the Galleri trial’s failure could lead to a more cautious approach to the rollout of multi-cancer early detection tests. Further research will be required to demonstrate the clinical utility of these tests before widespread adoption. The FDA’s shift in focus could lead to changes in the approval processes for digital health technologies and existing pharmaceutical treatments.

Frequently Asked Questions

What happened with the Galleri test?

Grail’s Galleri blood test failed to meet its primary endpoint in a make-or-break NHS trial.

What changes are happening at the FDA?

The FDA has appointed an AI industry veteran to lead digital health and a new CDER chief who intends to revisit SSRIs in pregnancy and scrutinize RSV monoclonals.

What is the significance of the Galleri trial failure?

The failure raises questions about whether earlier cancer detection actually changes outcomes, or just the timeline for diagnoses.

How might these developments impact the future of cancer screening and pharmaceutical regulation?